Bringing together real-time monitoring, telemedicine, AI, interventions, and pharmaceuticals into a single device produces a number of potential pitfalls.
Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
As suppliers can impact product quality, device manufacturers must oversee them as though they were an extension of the company and not an outside entity.
Whether an earthquake or the spread of the coronavirus, recent incidents highlight the reality and complexity associated with managing a global supply chain.
The start of the '20s offers the industry an opportunity to build value through new tech., collaborations, clinical validations, and value-based outcomes.
As companies undertake new types of analytics projects that require new skills beyond simple sales reporting, it’s worth revisiting the “build vs. buy” question